SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 221,798.45 |
| Enterprise Value ($M) | 245,394.45 |
| Book Value ($M) | 44,560.00 |
| Book Value / Share | 17.62 |
| Price / Book | 4.98 |
| NCAV ($M) | -32,611.00 |
| NCAV / Share | -12.89 |
| Price / NCAV | -6.80 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | 0.21 |
| Return on Assets (ROA) | 0.16 |
| Return on Equity (ROE) | 0.41 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 1.15 |
| Current Ratio | 1.36 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 40,361.00 |
| Assets | 117,532.00 |
| Liabilities | 72,972.00 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 64,168.00 |
| Operating Income | 22,765.00 |
| Net Income | 17,117.00 |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Vanguard Group Inc | 9.66 | 7.73 | |
| 13G/A | BlackRock, Inc. | 8.00 | -6.13 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 1,601,746 | 11,865,924 | 13.50 | |
| 1,678,646 | 11,463,167 | 14.64 | |
| 1,646,118 | 14,305,075 | 11.51 | |
| 1,208,850 | 18,695,780 | 6.47 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| HYAC – Haymaker Acquisition Corp. 4 | JNJ – Johnson & Johnson |
| LLY – Eli Lilly and Company | NUVB – Nuvation Bio Inc. |
| OGN – Organon & Co. |